Table 1.
Patient characteristics on day 7 after kidney transplantation.
| Characteristics | CYP3A5 expressers | CYP3A5 non-expressers | ||
|---|---|---|---|---|
| Placebo (n = 12) | Diltiazem (n = 11) | Placebo (n = 8) | Diltiazem (n = 9) | |
| Female, n (%) | 3 (25.0) | 6 (54.5) | 4 (50.0) | 2 (22.2) |
| Age, years | 48 (44, 56) | 34 (30, 58) | 42 (35, 58) | 38 (33, 57) |
| Body weight, kg | 60.8 ± 13.8 | 51.7 ± 10.4 | 59.3 ± 13.4 | 55.7 ± 11.0 |
| Height, m | 1.64 (1.60, 1.70) | 1.60 (1.55, 1.70) | 1.58 (1.55, 1.70) | 1.64 (1.56, 1.67) |
| Cause of ESRD, n (%) | ||||
| Diabetes Mellitus | 3 (25.0) | 0 (0) | 2 (25.0) | 2 (22.2) |
| Hypertension | 1 (8.3) | 1 (9.1) | 0 (0) | 0 (0) |
| Chronic glomerulonephritis | 0 (0) | 3 (27.3) | 0 (0) | 1 (11.1) |
| IgA nephropathy | 2 (16.7) | 1 (9.1) | 1 (12.5) | 0 (0) |
| Other | 1 (8.3) | 1 (9.1) | 3 (37.5) | 1 (11.1) |
| Unknown | 5 (41.7) | 5 (45.5) | 2 (25.0) | 5 (55.6) |
| Donor age, years | 35 (24, 44) | 33 (30, 48) | 38 (23, 41) | 38 (32, 41) |
| Female donor, n (%) | 8 (66.7) | 7 (63.6) | 3 (37.5) | 5 (55.6) |
| RRT before KT, n (%) | ||||
| Preemptive | 5 (41.7) | 2 (18.2) | 0 (0) | 2 (22.2) |
| Hemodialysis | 5 (41.7) | 8 (72.7) | 6 (75.0) | 7 (77.8) |
| Peritoneal dialysis | 2 (16.7) | 1 (9.1) | 2 (25.0) | 0 (0) |
| Dialysis vintage, months | 3 (0, 17) | 15 (1, 22) | 14 (10, 32) | 15 (1, 46) |
| Number of HLA mismatch | 3.0 (0.5, 4.5) | 3.0 (2.0, 5.0) | 2.5 (2.0, 3.0) | 3.0 (2.5, 4.5) |
| Presence of pre-transplant HLA antibodiesa, n (%) | ||||
| DSA | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Non-DSA | 5 (41.7) | 2 (18.2) | 3 (37.5) | 2 (22.2) |
| Serum creatinine, mg/dL | 1.19 (1.04, 1.67) | 1.10 (0.97, 1.53) | 1.02 (0.78, 1.30) | 1.13 (0.96, 1.60) |
| Hemoglobin, g/dL | 11.0 ± 2.0 | 11.3 ± 2.2 | 10.5 ± 1.7 | 10.8 ± 1.4 |
| Albumin, g/dL | 3.6 (2.9, 3.8) | 3.7 (3.4, 3.9) | 3.3 (3.2, 3.4) | 3.7 (3.5, 3.9) |
| Aspartate transaminaseb, U/L | 17 (12, 33) | 15 (10, 22) | 17 (14, 21) | 17 (10, 23) |
| Alanine transaminaseb, U/L | 17 ± 8 | 15 ± 4 | 13 ± 7 | 19 ± 8 |
| Total bilirubinb, mg/dL | 0.43 ± 0.12 | 0.39 ± 0.16 | 0.43 ± 0.13 | 0.48 ± 0.20 |
| Direct bilirubinb, mg/dL | 0.15 (0.13, 0.19) | 0.13 (0.11, 0.20) | 0.15 (0.13, 0.17) | 0.19 (0.10, 0.30) |
Values are expressed as count (%), mean ± SD, or median (interquartile range) for comparison reasons.
ESRD end stage renal disease, DSA donor-specific antibody, HLA human leukocyte antigen, KT kidney transplantation, RRT renal replacement therapy.
aDetection by single-antigen bead analysis, with mean fluorescence intensity of greater than or equal to 1500 (LABScreen Luminex kits, One Lambda, Canoga Park, CA, USA).
bData on day − 2 before kidney transplantation.